Westlake Epoxy Confirms ISCC+ Certification at Its Pernis, Netherlands Site
Westlake Corporation (NYSE: WLK) today announced that Westlake Epoxy’s Pernis, Netherlands site has completed the first sale of certified mass balanced Bisphenol A (BPA). Additionally, the site received mass balance certification for its tracing and handling of sustainable materials in the production of epoxy products for its International Sustainability & Carbon Plus (ISCC+) certification. This is a significant step in Westlake Epoxy’s strategy to integrate renewable carbon materials into its raw material supply chain while reducing energy use and greenhouse gas emissions.
All hydrocarbon feedstocks for the liquid epoxy resins produced at the Pernis location have been certified by mass balance to be replaceable by bio-based alternatives. These include the phenol and acetone used to manufacture BPA, as well as the propylene used to manufacture epichlorohydrin (ECH).
ISCC+ provides an international, practical, transparent system for the certification of bio-based, bio-circular and circular raw materials at each level of the supply chain. The ISCC+ certification recognizes Westlake Epoxy’s commitment to environmentally, socially and economically sustainable production by tracking its existing mix of feedstocks and replacing fossil materials with renewable resources.
This recent certification reflects Westlake’s ongoing commitment to operating in a more environmentally responsible manner. Recently, Westlake Epoxy’s European operations also received its second Platinum rating from EcoVadis, the world’s largest- and most-trusted provider of business sustainability ratings. Westlake Epoxy serves a variety of industries including adhesives, aerospace, automotive, civil engineering and construction, composite and wind energy, electronics, electric laminates and marine and protective coatings.
Westlake Corporation (NYSE: WLK) is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe, and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the company's web site at www.westlake.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005756/en/
Chip Swearngan, 1-713-960-9111
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Climate Impact X Launches CIX Exchange to Level up Carbon Market Transparency, Certainty and Liquidity8.6.2023 02:00:00 CEST | Press release
Climate Impact X (CIX), a global marketplace, auctions house and exchange for trusted carbon credits, has successfully launched its spot trading platform, CIX Exchange, completing the company’s core solutions suite with three operational venues. Powered by Nasdaq's trading technology, CIX Exchange offers carbon market professionals a customised experience built on international best practices for platform stability, performance and governance. Users can efficiently discover market-driven prices, compare individual projects and trade standard contracts. To address industry calls for greater transparency and price certainty, CIX has introduced the first daily on-exchange liquidity window in the voluntary carbon market with firm bids and offers. This dedicated 30-minute pricing session pools all-day liquidity from Asia, Europe and Middle East to help sharpen benchmark prices and improve order depth for spot nature-based credits. By close of trading on 7 June 2023, bids and offers had conv
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product7.6.2023 23:12:00 CEST | Press release
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict
IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 22:18:00 CEST | Press release
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 21:00:00 CEST | Press release
Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla
Brenus Pharma announces its international Scientific Committee7.6.2023 18:00:00 CEST | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLIMD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL2, Dijon. (FR) Head of the Board Pr Ahmad AWADAMD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active memb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom